pamapimod (RO4402257) / Roche - LARVOL DELTA

The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 (clinicaltrials.gov) - P2 | N=17 | Terminated | Sponsor: Kinarus AG | N=400 ➔ 17 | Suspended ➔ Terminated; Sponsor went bankrupt - trial was discontinued due to lack of financing

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients. (PubMed, iScience) - "The clinical trial was stopped for futility, mainly due to a lower-than-expected incidence of the primary endpoint. KIN001 was safe and well-tolerated but had no significant effect on clinical outcome."

Journal • P2 data • Fibrosis • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 (clinicaltrials.gov) - P2 | N=400 | Suspended | Sponsor: Kinarus AG | Trial completion date: Oct 2023 ➔ Oct 2025 | Recruiting ➔ Suspended | Trial primary completion date: May 2023 ➔ May 2025

Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Kinarus AG

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. (PubMed, Int J Mol Sci) - "Recently, the protease inhibitor Paxlovid and the polymerase inhibitor molnupiravir, both targeting mutant-prone viral components, were approved for high-risk COVID-19 patients. Both drugs showed similar antiviral potency across several cultured cell types and similar antiviral activity against SARS-CoV-2 Wuhan type, and the VoCs Alpha, Beta, Gamma, Delta, and Omicron. These data support the combination of pamapimod and pioglitazone as a potential therapy to reduce duration and severity of disease in COVID-19 patients, an assumption currently evaluated in an ongoing phase II clinical study."

Journal • Diabetes • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

Repurposing of gastric cancer drugs against COVID-19. (PubMed, Comput Biol Med) - "In this study, we have found 12 kinase inhibitors with high binding energies namely Baricitinib, Brepocitinib, Decernotinib, Fasudil, Filgotinib, GSK2606414, Peficitinib, Ruxolitinib, Tofacitinib, Upadacitinib, Pamapimod and Ibrutinib. Taken altogether, we have proposed the SARS-CoV-2-RdRp as a potential therapeutic target through in-silico studies. However, further in-vitro and in-vivo studies are required for the validation of the proposed targets and drugs for the treatment of COVID-19 patients already suffering from GC."

Journal • Gastric Cancer • Gastrointestinal Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor • FGFR2 • SYK • TYK2

Inhibition against p38/MEF2C pathway by Pamapimod protects osteoarthritis chondrocytes hypertrophy. (PubMed, Panminerva Med) - "PAM protects CHs hypertrophy by the inhibition of the p38/MEF2C pathway."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • MMP13

The Novel p38 Inhibitor, Pamapimod, Inhibits Osteoclastogenesis and Counteracts Estrogen-Dependent Bone Loss in Mice. (PubMed, J Bone Miner Res) - "In conclusion, our results demonstrated PAM can prevent OVX-induced bone loss through suppression of p38/NFATc1-induced osteoclast formation and NFATc1/ADAM12-associated bone resorption."

Journal • Preclinical • Immunology • Osteoporosis • Rheumatoid Arthritis • Rheumatology